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Thromboxane A2-Induced Inhibition of Voltage-Gated K
Channels and Pulmonary Vasoconstriction
Role of Protein Kinase C
Angel Cogolludo, Laura Moreno, Lisardo Bosca, Juan Tamargo, Francisco Perez-Vizcaino
Abstract—Voltage-gated K channels (KV) and thromboxane A2 (TXA2) play critical roles in controlling pulmonary
arterial tone under physiological and pathological conditions. We hypothesized that TXA2 might inhibit KV channels,
thereby establishing a link between these two major pathogenic pathways in pulmonary hypertension. The TXA2
analogue U46619 inhibited IK(V) (Emax56.13.9%, EC500.0540.019 mol/L) and depolarized pulmonary artery
smooth muscle cells via activation of TP receptors. In isolated pulmonary arteries, U46619 simultaneously increased
intracellular Ca2 concentration and contractile force, and these effects were inhibited by nifedipine or KCl
(60 mmol/L). U46619-induced contractions were not altered by the inhibitors of tyrosine kinase genistein or Rho kinase
Y-27632 but were prevented by the nonselective protein kinase C (PKC) inhibitors staurosporine and calphostin C.
Furthermore, these responses were sensitive to Gö-6983 but insensitive to bisindolylmaleimide I and Gö-6976. Based
on the specificity of these drugs, we suggested a role for an atypical PKC in U46619-induced effects. Thus, treatment
with a PKC pseudosubstrate inhibitor markedly prevented the vasoconstriction, the inhibition of IK(V), and the
depolarization induced by U46619. Western blots showed a transient translocation of PKC from the cytosolic to the
particulate fraction on stimulation with U46619. These results indicate that TXA2 inhibits IK(V), leading to depolarization,
activation of L-type Ca2 channels, and vasoconstriction of rat pulmonary arteries. We propose PKC as a link between
TP receptor activation and KV channel inhibition. (Circ Res. 2003;93:656-663.)
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Thromboxane A2 (TXA2) is a prostanoid synthesized bycyclooxygenase with potent vasoconstrictor, mitogenic,
and platelet aggregant properties.1 The vasoconstrictor effects
of TXA2 are particularly pronounced in the pulmonary
vascular bed, where it participates in the control of vessel
tone under physiological and pathological situations. In fact,
TXA2 has been involved in several forms of human and
experimental pulmonary hypertension, including primary2
and secondary pulmonary hypertension induced by sepsis,
endotoxemia, heparin/protamine, leukotriene D4, microembo-
lism, and ischemia-reperfusion.3–8
TXA2 contracts vascular smooth muscle by binding to
specific Gq/11 protein– coupled receptors (TP receptors),
which leads to an increase in intracellular Ca2 concentration
([Ca2]i) and sensitization of the contractile proteins to
Ca2.9–12 Activation of TP receptors is also involved in the
vasoconstrictor effects of several isoprostanes, a novel class
of arachidonic acid metabolites generated by oxygen free
radical–mediated peroxidation of membrane phospholipids,
used as markers for many disease states, including pulmonary
hypertension.13 The signaling pathways mediating TP recep-
tor–induced contraction remain controversial, because a va-
riety of protein kinases, such as protein kinase C (PKC), Rho
kinase, and tyrosine kinases, have been shown to be
involved.9,10,12
K channels play an essential role in regulating resting
membrane potential, [Ca2]i, and contraction of vascular
smooth muscle.14–18 Activation of K channels leads to
hyperpolarization, whereas their inhibition causes membrane
depolarization, activation of voltage-gated L-type Ca2 chan-
nels, increase in [Ca2]i, and vasoconstriction. Different types
of K channels have been identified in pulmonary artery
smooth muscle cells (PASMCs), including voltage-gated K
channels (KV), large-conductance Ca2–activated channels
(BKCa), and ATP-dependent channels (KATP).14,17–19 There is
increasing interest in KV channels in the pulmonary circula-
tion because of several different facts. First, they make a
substantial contribution to whole-cell K conductance and
resting membrane potential in PASMCs.14,15,18 Second, they
are modulated by hypoxia and vasoactive factors such as
nitric oxide, endothelin-1, and angiotensin II.14,19–21 Finally,
decreased expression or function of KV channels in PASMCs
has been involved in the pathogenesis of primary and
anorexigen-induced pulmonary hypertension.14,22–24
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Very little is known about the effects of TXA2 on vascular
K channels. It has been reported that TXA2 analogues inhibit
the activity of BKCa channels in bronchial and coronary
arteries,25,26 whereas their effects on vascular KV channels are
unknown. We hypothesized that TXA2 might inhibit KV
channels, thereby establishing a link between these two
pathogenic pathways in pulmonary hypertension. Therefore,
in the present study we have analyzed the effects of the TXA2
analogue U46619 on the current flowing through KV channels
(IK(V)) recorded in rat PASMCs using the whole-cell config-
uration of the patch-clamp technique. The role of KV channels
in TXA2-induced pulmonary vasoconstriction has also been
studied in isolated pulmonary arteries (PAs). Our results
indicate that U46619 inhibits KV channels, leading to depo-
larization of PASMCs, an increase in [Ca2]i, and vasocon-
striction in PA. Furthermore, we provide evidence for the role
of PKC as the link between TXA2 receptor activation and
inhibition of KV channels.
Materials and Methods
All experiments were carried out in accordance with the European
Animals Act 1986 (Scientific Procedures) and approved by our
institutional review board.
Reagents
Drugs were obtained from Sigma, except nifedipine (Bayer España),
Y-27632 (Tocris Cookson), fura-2 AM, calphostin C, Gö-6976,
Gö-6983, PKC pseudosubstrate inhibitor, and secondary horserad-
ish peroxidase–conjugated antibodies (Calbiochem). Polyclonal rab-
bit antibodies were from Santa Cruz Biotechnology.
Tissue Preparation and Cell Isolation
Second- to third-order branches of the PA (internal diameter, 0.5 to
1 mm) isolated from male Wistar rats (250 to 300 g; ANUC,
Universidad Complutense, Madrid, Spain) were dissected into a
nominally calcium-free physiological salt solution (Ca2-free PSS)
of the following composition (in mmol/L): NaCl 130, KCl 5, MgCl2
1.2, glucose 10, and HEPES 10 (pH 7.3 with NaOH). Endothelium-
denuded PAs were cut into small segments (22 mm), and cells
were isolated in Ca2-free PSS containing (in mg/mL) papain 1,
dithiothreitol 0.8, and albumin 0.7. Cells were stored in Ca2-free
PSS (4°C) and used within 8 hours of isolation.
Contractile Tension Recording
Contractile responses in endothelium-denuded PA rings were rec-
orded as previously reported.9,27 Arteries were stimulated with
U46619 (0.1 mol/L) and, once a stable contraction was reached,
were washed with Krebs solution for 30 minutes. A second stimu-
lation with U46619 was elicited in the absence of treatment (con-
trols) or after 30 minutes of treatment with different drugs. The
values of the second contraction were expressed as a percentage of
the initial response to the agonist and normalized to the values
obtained in control experiments.
Simultaneous [Ca2]i and Tension Recording
PA rings were incubated for 2 to 3 hours in Krebs solution containing
fura-2 acetoxymethylester (5 mol/L) and Cremophor EL (0.05%)
and then mounted in a bath that allows the estimation of changes in
the fluorescence intensity of fura-2 and force development simulta-
neously.9,28 The absolute values of [Ca2]i were estimated using the
Grynkiewicz equation.9,29
Electrophysiological Studies
Membrane currents were measured using the whole-cell configura-
tion of the patch-clamp technique,30 normalized for cell capacitance
and expressed in pA pF1. Membrane potential (Em) was measured
under current-clamp configuration.
KV currents (IK(V)) were recorded under essentially Ca2-free
conditions using an external Ca2-free PSS (see above) and a
Ca2-free pipette (internal) solution containing (in mmol/L) KCl 110,
MgCl2 1.2, Na2ATP 5, HEPES 10, and EGTA 10, pH adjusted to 7.3
with KOH. For recording L-type Ca2 currents, KCl was replaced by
CsCl in both the external and the pipette solutions and 10 mmol/L
BaCl2 was included in the external solution as charge carrier. All
experiments were performed at room temperature (22 to 24°C).
Western Blot Analysis, Phosphorylation of T410,
and Cell Fractionation
After dissection, PAs were placed in warm, oxygenated Krebs
solution for 60 minutes and then in the absence or presence of
U46619 (1 mol/L) for 30 or 180 seconds. PAs were frozen in liquid
nitrogen, homogenized in a glass potter in 200 L of a buffer of the
following composition: 10 mmol/L HEPES (pH 8), 10 mmol/L KCl,
1 mmol/L EDTA, 1 mmol/L EGTA, 1 mmol/L dithiothreitol, 40
g/mL aprotinin, 4 g/mL leupeptin, 4 g/mL N-p-tosyl-L-lysine
chloromethyl ketone, 5 mmol/L NaF, 10 mmol/L Na2MoO4,
1 mmol/L NaVO4, 0.5 mmol/L phenylmethanesulfonyl fluoride, and
10 nmol/L okadaic acid. The homogenate was centrifuged at
100 000g for 30 minutes. The supernatant was collected (cytosolic
fraction), and the pellet was resuspended in 200 L of the same
buffer containing nonidet P-40 1% and gently shaken for 30 minutes
at 4°C and again centrifuged at 100 000g for 30 minutes. The pellet
was discarded, and the supernatant was collected (particulate-
enriched fraction). The enrichment of the subcellular fractions was
evaluated by measuring the levels of cytosolic and membrane
markers. Western blotting was performed with 10 g of protein from
the supernatant per lane. SDS-PAGE (7.5% acrylamide) electro-
phoresis was performed using the method of Laemmli in a mini-gel
system (Bio-Rad). The proteins were transferred to PVDF mem-
branes overnight at 4°C and incubated with rabbit anti-PKC,
anti-PKC, or anti-P-T410-PKC primary antibodies and secondary
anti-rabbit horseradish peroxidase–conjugated antibodies. The bands
were visualized by chemoluminescence (ECL, Amersham).
Statistical Analysis
Data are expressed as meanSEM; n indicates the number of arteries
or cells tested from different animals. Statistical analysis was
performed using Student’s t test for paired observations or one-way
ANOVA followed by a Newman-Keuls test. Differences were
considered statistically significant when P0.05.
Results
Effects of the TXA2 Analogue U46619 on IK(V) and
Membrane Potential
The average cell capacitance of the freshly isolated rat
PASMC was 17.40.6 pF (n42). IK(V) was recorded under
essentially Ca2-free conditions, and EGTA and ATP were
included in the pipette solution to minimize the component of
ATP-dependent (IK(ATP)) and Ca2-activated (IBK(Ca)) K cur-
rents. Under these conditions, when cells were voltage-
clamped at 60 mV, the application of 200-ms depolarizing
pulses to test potentials from 60 to 50 mV in 10-mV
increments induced a K current (Figure 1A), which activated
at potentials positive to 30 mV and was usually reproduc-
ible for at least 1 hour. This current was essentially abolished
by the KV channel inhibitor 4-aminopyridine (1 mmol/L,
Figures 1F and 1G), indicating that it was evoked by the
activation of KV channels. U46619 inhibited IK(V) in a
concentration-dependent manner (Figures 1A and 1B). The
onset of the response to U46619 was fast (20 to 30 seconds)
and reached a stable response within 2 to 3 minutes. The
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concentration-response curve for the inhibition of IK(V) by
U46619 at test potentials of 50 mV was fitted to a Hill
equation, leading to Emax and EC50 values of 56.13.9% and
0.0540.019 mol/L, respectively (Figure 1C). The magni-
tude of this inhibition was similar at the potentials tested,
indicating a voltage-independent blockade (Figure 1D). In
addition, U46619 (0.1 and 1 mol/L) significantly depolar-
ized PASMCs in a concentration-dependent manner (Figure
1E).
In the presence of the TXA2 receptor antagonist SQ-29548
(3 mol/L), U46619 (0.1 mol/L) did not modify the KV
currents or the membrane potential in isolated PASMCs
(Figures 2A and 2B). These results indicated that the elec-
trophysiological effects induced by U46619 were mediated
through the activation of TP receptors.
Effects of U46619 on Contraction and [Ca2]i:
Role of L-Type Ca2 Channels
Stimulation of endothelium-denuded PA rings with U46619
(0.1 mol/L, which produced 50% of the maximal re-
sponse) induced a sustained contractile response of 18523
mg (n10), which was suitably reproduced after a 30-minute
washout (1094% of the first contraction, P0.05). Pretreat-
ment with 3 mol/L SQ-29548 before the second addition of
U46619 completely abolished the vasoconstriction (Figure
2C).
Depolarization resulting from U46619-induced inhibition
of KV channels might increase vascular tone by promoting
Ca2 entry through voltage-gated L-type Ca2 channels. This
possibility was studied by measuring simultaneous changes in
force and [Ca2]i in fura-2-loaded PA. Absolute values for
[Ca2]i under basal conditions and after stimulation with
U46619 (0.1 mol/L) were 29996 and 49055 nmol/L,
respectively, and the sustained contractile response averaged
16334 mg (n5).
Both the increase in [Ca2]i and the increase in force
induced by U46619 (0.1 mol/L) were reproducible (Figure
3A) and markedly inhibited in the presence of the L-type Ca2
channel–blocker nifedipine (0.1 mol/L, Figure 3B). Simi-
larly, pretreatment with KCl (60 mmol/L) elicited a contrac-
tion of 14521% of the response to U46619 and markedly
inhibited the contraction and abolished the increase in [Ca2]i
induced by U46619 (Figure 3C). These results suggested an
important role of L-type Ca2 channels in the U46619-
induced increase in [Ca2]i and contraction. Figure 3E shows
the concentration-response curves for the increase in [Ca2]i
and force induced by U46619 (0.01 to 3 mol/L), which
yielded EC50 values of 0.130.01 and 0.140.01 mol/L,
respectively (n6).
To test the possibility that U46619 could be modulating
L-type Ca2 channels not only via membrane depolarization
but also directly, its effects were analyzed on L-type Ca2
currents recorded in isolated PASMCs. Figure 4A shows
traces of Ca2 currents elicited when stepping from 60 to
10 mV. The current activated at 27 mV reached a
maximum at 10 mV (Figure 4B) and was not significantly
affected by U46619 (0.1 mol/L) but was completely abol-
ished by nifedipine (0.1 mol/L).
Role of Protein Kinases on U46619-Induced Effects
To additionally assess the mechanisms involved in U46619-
induced contraction, PAs were incubated with different pro-
tein kinase inhibitors before the second addition of the
agonist. As shown in Figure 5A, neither the tyrosine kinase
inhibitor genistein (10 mol/L) nor the Rho kinase inhibitor
Y-27632 (1 mol/L) modified U46619-induced contraction,
whereas the PKC inhibitors staurosporine (0.01 mol/L) and
calphostin C (1 mol/L) markedly attenuated the response to
the TXA2 analogue. Because staurosporine is a nonselective
inhibitor of PKC and may also directly affect contractile
proteins (eg, it inhibits myosin light chain kinase31), we
analyzed its effects on 4-aminopyridine-induced contractions.
At 10 mmol/L, 4-aminopyridine elicited a contractile re-
sponse of 15914 mg (n8). Staurosporine (0.01 mol/L)
did not affect the contraction induced by 4-aminopyridine
(16215 mg; n9; P0.05), suggesting that at this concen-
tration the drug had no direct effect on contractile proteins.
In PASMCs, Y-27632 (1 mol/L) did not significantly
modify the membrane potential or IK(V) and did not alter the
depolarizing (not shown) or KV channel inhibitory effects
Figure 1. U46619 decreases IK(V) rec-
orded in rat PASMCs. A, Current traces
are shown for 200-ms depolarization
pulses from 60 mV to 50 mV (in
10-mV increments) from a holding poten-
tial of 60 mV. U46619 (0.1 and 1
mol/L) inhibited IK(V) in a concentration-
dependent manner. B, Current-voltage
relationships of IK(V) measured at the end
of the pulse to 50 mV in the absence
and the presence of U46619 (0.1 and 1
mol/L). C, Concentration-dependent
inhibition of IK(V) by U46619. D, Voltage
dependency of the effects of U46619
(0.1 mol/L) on IK(V) measured at 200 ms.
The inhibitory effect resulted to be volt-
age independent. E, Effects of U46619
on membrane potential. The drug depo-
larized the membrane in a concentration-
dependent manner. F, Current traces when applying depolarization pulses to 50 mV from a holding potential of 60 mV in the
absence (control) and presence of 4-aminopyridine (4-AP, 1 mmol/L). G, Current-voltage relationships of IK(V) in the absence and the
presence of 4-AP. Data show meanSEM (n4 to 7). *P0.05 and **P0.01 vs control, respectively.
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induced by 0.1 mol/L U46619 (Figure 5B). Perfusion with
staurosporine (0.1 mol/L) did not alter IK(V) but prevented
the U46619-induced inhibition of this current (Figure 5C).
Role of PKC in U46619-Induced Effects
In view of the preceding data, we performed pharmacological
studies with isotype-selective PKC inhibitors to evaluate the
involvement of specific PKC isoforms in U46619-induced
contractions. The inhibitors used were bisindolylmaleimide I,
which at the concentration tested shows selectivity for the
conventional PKC (cPKC) isoforms (, I, II, and ) and
for some novel PKC (nPKC) isoforms ( and ); Gö-6976,
which inhibits cPKC isoforms and PKC; and Gö-6983,
which preferentially inhibits cPKC, some nPKC, and the
atypical (aPKC) PKC but not PKC.31,32 No changes were
observed in U46619-induced contraction when PAs were
pretreated with 1 mol/L bisindolylmaleimide I or 0.01
mol/L Gö-6976 (Figure 6A). However, exposure to Gö-
6983 (0.01 mol/L) markedly inhibited U46619-induced
contraction. Because the only isoform known to be sensitive
to Gö-6983 and insensitive to the other two drugs is PKC,
we hypothesized that this aPKC might be involved in the
responses induced by U46619. Therefore, we examined the
effects of a PKC pseudosubstrate inhibitor (PKC-PI, 10
mol/L). Figure 6A shows that PKC-PI produced an inhi-
bition of U46619-induced pulmonary vasoconstriction simi-
lar to that induced by Gö-6983.
In PASMCs, U46619 did not alter IK(V) in the presence of
0.1 mol/L Gö-6983 (which very slightly reduced IK(V) by
10.76.8%, P0.05, Figure 6B). Similarly, in cells dialyzed
with an internal solution containing 0.1 mol/L PKC-PI, the
addition of U46619 had no effect on IK(V) (Figure 6C) or
membrane potential (Em47.21.5 and 47.91.3 mV
before and after adding U46619, respectively). Altogether,
these results indicated a key role of PKC in TXA2-induced
inhibition of IK(V), depolarization, and contraction of PA.
Subcellular Distribution of aPKC
Numerous reports in the literature using antibodies raised
against the C-terminal domain of PKC found two bands of
75 to 80 kDa in fibroblasts, rabbit and ferret aorta, rat
cardiac myocytes, PC12 cells, murine epidermis, basophilic
RBL-2H3 cells, Jurkat T lymphoma cells, rat embryo fibro-
blasts, NIH 3T3 cells, the J774 macrophage cell line, the
T3-1 gonadotroph-derived cell line, rat brain, and bovine
kidney cells (Reference 33 and references therein). The upper
band is Ca2-dependent, can be downregulated by phorbol
esters, and is actually considered a cPKC.33 Western blots of
homogenates from rat PA using polyclonal rabbit antibody
directed toward the C-terminal peptide of PKC also recog-
nized two bands of 81 and 75 kDa (Figure 6D). This
antibody cross-reacts with the aPKC	/. However, the ex-
pression of this aPKC was negligible using a specific anti-
PKC	/ antibody toward the amino acids 168 to 243 of PKC
of human origin (equivalent to rodent PKC	). Furthermore,
an antibody directed toward the phosphorylated activation
loop (T410) of PKC clearly identified the lower band even
when the heavier one was also present in some blots. This
indicates that an aPKC, most probably PKC, is strongly
expressed and is at least partly phosphorylated at T410 in
resting rat PA. Because the activity of PKC is mostly
controlled by its intracellular compartmentalization, we ana-
lyzed its subcellular distribution and its possible translocation
on stimulation with U46619. The 81-kDa band was located
mostly in the particulate fraction (825%), and its cytosolic/
particulate distribution did not change in PA stimulated with
U46619. However, the 75-kDa band was less abundant in the
particulate fraction (387%) and was rapidly but transiently
translocated to the membrane fraction on U46619 stimulation
(Figure 6D).
Discussion
In the present study, we have examined the effects of the
TXA2 analogue U46619 on KV channels in freshly isolated
Figure 2. TP receptor activation mediates U46619-induced
effects. Pretreatment with the TP receptor antagonist SQ-29548
(3 mol/L) suppressed the effects of U46619 (0.1 mol/L) on IK(V)
(A) and membrane potential (B) in PASMCs and on contractile
tension in PA (C). Data show meanSEM (n4 to 6). **P0.01
vs control.
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PASMCs and its role in [Ca2]i and contraction in rat PA. We
have demonstrated for the first time that U46619, through the
activation of TP receptors, inhibited IK(V) and depolarized
PASMCs in a concentration-dependent manner. These effects
were totally abolished by nonselective PKC inhibitors and by
selective inhibition of aPKCs. Additionally, the U46619-
induced increases in [Ca2]i and contraction of the PA were
markedly attenuated by L-type Ca2 channel blockade, al-
though this vasoconstrictor did not directly affect L-type Ca2
currents. PKC was strongly expressed in PA and was
translocated on stimulation with U46619, whereas expression
of the other aPKC (PKC	/) was negligible. All of these
results indicate that U46619, via PKC-dependent pathway,
inhibits KV channel activity and causes membrane depolar-
ization, leading to the activation of L-type Ca2 channels,
increase in [Ca2]i, and contraction of PASMCs.
Membrane potential plays an essential role in regulating
vascular diameter through the control of Ca2 influx and,
therefore, [Ca2]i. In PASMCs, the resting membrane poten-
tial seems to be predominantly regulated by KV chan-
nels.14–16,21,23 Herein, we show that U46619 (via activation of
TP receptors) inhibits KV channels and depolarizes the
membrane of PASMCs to values above the threshold of
activation of L-type Ca2 channels15,18 and causes an increase
in [Ca2]i and vasoconstriction. The fact that its effects on
[Ca2]i and vasoconstriction are dihydropyridine-sensitive is
Figure 3. U46619 increases force and [Ca2]i via L-type Ca2 channels. Recordings of the simultaneous changes on force (top) and
[Ca2]i (bottom) elicited by U46619 (0.1 mol/L). The second stimulation with U46619 was elicited in the absence (control, A) or after
exposure to nifedipine (0.1 mol/L, B) or KCl (60 mmol/L, C). D, MeanSEM of 5 to 6 experiments, as those presented in panels A
through C. Values were normalized to those obtained in control conditions (**P0.01 vs control). E, Concentration response curves for
the increase in [Ca2]i and contractile force induced by U46619 (0.01 to 3 mol/L, meanSEM, n6).
Figure 4. U46619 has no effect on L-type Ca2 currents rec-
orded in PASMCs. A, Current traces are shown when stepping
from 60 mV to 10 mV in the absence (control) and presence
of U46619 (0.1 mol/L) or nifedipine (0.1 mol/L). B, Current-
voltage relationships of L-type Ca2 currents measured at the
peak in the absence and the presence of U46619. Data show
meanSEM (n5).
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widely assumed to involve a direct activation of TXA2 on
L-type Ca2 channels.11 However, such assumption has never
been demonstrated, and, in fact, a blockade of these channels
by TXA2 agonists has been described in rat hippocampal CA1
neurons.34 In the present study, L-type Ca2 currents were not
affected by U46619 but were abolished by nifedipine. There-
fore, our results are consistent with earlier studies demon-
strating the involvement of L-type Ca2 channels in TXA2-
induced vasoconstriction11 but highlight a relevant role for KV
channels as key modulators linking TP receptors to L-type
Ca2 channels in rat PA. However, our results cannot rule out
that other mechanisms may also contribute to the contraction
induced by the activation of TP receptors. Thus, there is a
residual component of the contraction that is independent of
changes in [Ca2]i (ie, implies Ca2 sensitization9,10) and on
the signaling events described herein.
TXA2-induced pulmonary vasoconstriction has been
shown to be mediated through different intracellular signaling
cascades, such as PKC, tyrosine kinase, and Rho ki-
nase.9,10,12,27 In the present study, the analysis of the signaling
pathways involved in TXA2-induced effects revealed a lack
of involvement of tyrosine and Rho kinases. However, the
vasoconstrictor and electrophysiological effects of U46619
were attenuated by the nonselective PKC inhibitors stauro-
sporine and calphostin C. Because staurosporine per se did
not modify KV currents or the contraction induced by 4-ami-
nopyridine, the role of PKC in modulating KV channels seems
to be dependent on the activation of TP receptors. PKC
Figure 5. Inhibition of PKC decreases U46619-induced
responses. A, Effects of genistein (Genis, 10 mol/L), Y-27632
(1 mol/L), staurosporine (Stauro, 0.01 mol/L), and calphostin
C (Calphost, 1 mol/L) on U46619-induced contractions in rat
PA. Results are normalized to values obtained in control experi-
ments. Data represent meanSEM (n5 to 7). **P0.01 vs con-
trol. B and C, Effects of Y-27632 (1 mol/L) and Y-27632 plus
U46619 (0.1 mol/L) (B) and staurosporine (0.1 mol/L) and
staurosporine plus U46619 (0.1 mol/L) (C) on the current-
voltage relationships of IK(V) measured at the end of the pulse.
Data show meanSEM (n4).
Figure 6. PKC mediates the contractile and electrophysiologi-
cal effects induced by U46619. A, Effects of bisindolylmaleimide
I (Bisin, 1 mol/L), Gö-6976 (0.1 mol/L), Gö-6983 (0.1 mol/L),
and a pseudosubstrate inhibitor of PKC (PKC-PI, 10 mol/L)
on U46619-induced contractions in rat PA. Results are normal-
ized to values obtained in control experiments. Data represent
meanSEM (n5 to 12). **P0.01 vs control. B and C, Effects
of U46619 (0.1 mol/L) on IK(V) in the presence of Gö-6983 (0.1
mol/L) and PKC-PI (0.1 mol/L, in the internal pipette solu-
tion), respectively. The current-voltage relationships of IK(V) in the
presence of these drugs are also depicted. Data represent
meanSEM (n5 to 6). D, Subcellular distribution of atypical
PKCs. Top, Representative Western blots of cytosolic (C) and
particulate (P) enriched fractions of homogenates of PA under
resting conditions (0) or after exposure to U46619 (1 mol/L) for
30 and 180 seconds using an antibody directed against the
C-terminal domain of PKC. The graph shows the quantitative
distribution of the PKC bands in the particulate fraction (per-
cent of CP) as a function of time of U46619 exposure.
*P0.05 vs time 0 (meanSEM, n4 to 7). Bottom, Represen-
tative blots of total extracts of PA revealed with anti-PKC, anti-
P-T410 PKC, and anti-PKC 	/ antibodies.
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represents a family of several isoforms that can be divided
into cPKC (, I, II, and ), nPKC (, , 
, and ), and
aPKC ( and 	/) isoforms.31,32 The former group includes
Ca2-dependent isoforms, whereas nPKC and aPKC are
Ca2-independent. Several isoforms (, , , , and ) seem to
coexist in vascular smooth muscle cells,36,37 and their mod-
ulation may account for the responses of vasoconstrictor
agents such as angiotensin II, norepinephrine, and endothelin-
1.35,36,38 The contractile response to U46619 was sensitive to
Gö-6983 (which preferentially inhibits cPKC, , and  iso-
forms) but insensitive to bisindolylmaleimide I or to Gö-6976
at concentrations at which cPKC, , , and  isoforms should
be substantially blocked.31 These results suggest a role for an
aPKC in TXA2-induced effects. This proposal is additionally
supported by the fact that TXA2-induced inhibition of KV
channels was observed under Ca2-free conditions. A
pseudosubstrate inhibitor peptide, highly specific for PKC,
markedly inhibited the effects induced by U46619 on KV
channels and contractile force, which indicated a functional
role for PKC in the signal transduction after TP receptor
activation. In agreement with our results, PKC is also
involved in TXA2-induced apoptosis in ventricular myo-
cytes.39 The expression of PKC was confirmed by Western
blot analysis in rat PA (present results) and in cultured canine
pulmonary vascular smooth cells36 using an antibody directed
to the C-terminal peptide of PKC, which shows cross-
reactivity with PKC	/. However, the expression of PKC 	/
was negligible using the specific anti-PKC	/ antibody,
suggesting that the aPKC in this tissue is mainly PKC.
Furthermore, the results obtained with an antibody directed
toward the phosphorylated activation loop (T410) of PKC
indicate that this kinase is at least partly phosphorylated at
T410 in PA. Another piece of evidence in favor of the
involvement of PKC comes from the results of the transient
translocation of PKC from the cytosolic to the particulate-
enriched fraction on stimulation with U46619.
KV channels are composed by pore-forming KV and
modulatory KV subunits.16 The -subunits of KV channels
may play an important role in modulating the gating proper-
ties of -subunits. Interestingly, PKC, via PKC-interacting
proteins (ZIP1, ZIP2, and ZIP3) acting as scaffolds, has been
shown to phosphorylate the auxiliary KV2-subunit,40,41
whereas the consequences of this phosphorylation on KV
function were not analyzed. Therefore, we suggest that after
TP receptor activation, the translocation of PKC to the
membrane may facilitate its coupling with KV channels. ZIPs,
which dramatically enhance phosphorylation of KV subunits,
are attractive scaffold candidates in this interaction.
Increased activity of TXA2 is associated with several forms
of pulmonary hypertension.1–8 It is interesting to note that
calcium channel blockers are first-choice drugs in the treat-
ment of pulmonary hypertension.23,42 The present results
demonstrate that PKC translocation, KV channel inactiva-
tion, membrane depolarization, and L-type Ca2 channel
activation are key events mediating TXA2-induced pulmo-
nary vasoconstriction, establishing the rationale for the use of
calcium channel blockers in pulmonary hypertension associ-
ated with increased vasoconstrictors such as TXA2 and
isoprostanes activating TP receptors.
In conclusion, we demonstrate that in intact PAs and
freshly isolated PASMCs, TXA2, via activation of TP recep-
tors, inhibits KV channels, leading to membrane depolariza-
tion, activation of L-type Ca2 channels, elevation of [Ca2]i,
and vasoconstriction. PKC seems to play a major role as a
link between TP receptor activation and KV channel
inhibition.
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